The hub genes identified, especially CCNA2, CCNB2, CDK1, and TOP2A, represent promising biomarker candidates and potential therapeutic targets worthy of further investigation for improving early HCC detection and treatment outcomes. This evidence concerns the gene CCNA2 and hepatocellular carcinoma.